These results show that SULT1A1 is an efficient and selective catalyst of 2-MeOE 2 sulfonation and, as such,
Introduction
To whom correspondence should be addressed E-mail: spink@wadsworth.org Estrogens have long been associated with breast cancer. Based In a previous study of nine human breast-derived cell lines, on established risk factors, it is thought that the cumulative rates of metabolism of 17β-estradiol (E 2 ) were greatly exposure of a woman to endogenous and exogenous estrogens enhanced when cultures were exposed to the aromatic is an important determinant in susceptibility to this disease. hydrocarbon receptor agonist, 2,3,7,8-tetrachlorodibenzoStimulation of breast-cell proliferation has been proposed as p-dioxin. Elevated rates of E 2 hydroxylation at the C-2, -the main effect of estrogens in carcinogenesis. It has been 4, -6α and -15α positions were observed concomitant with hypothesized that the more rapidly cells proliferate, the greater the induction of cytochromes P450 1A1 and 1B1. In each the chance that random genetic errors will occur and will cell line, 2-and 4-hydroxyestradiol (2-and 4-OHE 2 ) were be propagated (1) (2) (3) (4) (5) . Estrogen metabolism has been studied converted to 2-and 4-methoxyestradiol (2-and 4-MeOE 2 ) extensively in the context of breast cancer, not only because by the action of catechol O-methyltransferase. In this study, various metabolic pathways affect estrogen availability, which conjugation of these estrogen metabolites was investigated.
would in turn affect gene transcription and epithelial cell A comparison of the levels of metabolites determined with proliferation, but also because it results in the formation of and without prior treatment of the media with a crude β-metabolites with physiological properties quite distinct from glucuronidase/sulfatase preparation showed that most of those of the parent hormone. the 2-MeOE 2 present was in conjugated form, whereas 4-
The potential consequences of alterations in estrogen metaMeOE 2 , 6α-OHE 2 and 15α-OHE 2 were minimally conjugbolism on the initiation and promotion of breast cancer are ated. Inhibitor studies suggested that it was the sulfatase varied and complex, as individual pathways have been activity of the preparation that hydrolyzed the 2-MeOE 2 described as promoting or inhibiting carcinogenesis. The conjugates in MCF-7 cell media; the presence of 2-MeOE 2 -4-and 16α-hydroxylation pathways of cytochrome P450-3-sulfate in MCF-7 culture media was confirmed by eleccatalyzed metabolism are thought to give rise to metabolites trospray ion-trap mass spectrometry. To identify the with carcinogenic potential (6) (7) (8) . Conversely, the 2-enzyme catalyzing this conjugation, the expression of hydroxylation pathway is thought to be anticarcinogenic. mRNAs encoding five sulfotransferases (SULT1A1, 2-Methoxyestradiol (2-MeOE 2 ), which is formed by the SULT1A2, SULT1A3, SULT1E1 and SULT2A1) was evalumethylation of 2-hydroxyestradiol (2-OHE 2 ), catalyzed by ated in the nine cell lines by use of the reverse transcriptioncatechol O-methyltransferase (COMT), is thought to be protectpolymerase chain reaction. Only expression of SULT1A1 ive against breast cancer, as antiproliferative, antiangiomRNA correlated with the observed conjugation of nanogenic and antitumorigenic properties have been attributed to molar levels of 2-MeOE 2 in these cell lines. Cloning and this metabolite (9, 10) . sequencing of SULT1A1 cDNA from MCF-7 cells revealed Efforts in this laboratory have been focused on characterizing that mRNAs encoding two previously identified allelic the metabolism of 17β-estradiol (E 2 ) within human breast variants, SULT1A1*1 ( 213 Arg) and SULT1A1*2 ( 213 His), epithelial and tumor cells and determining how this metabolism were expressed in these cells. Heterologous cDNA-directed is affected by exposure to endocrine-disrupting xenobiotics expression of either variant in MDA-MB-231 cells, which (11) (12) (13) (14) (15) (16) (17) . Our previous studies showed that exposure to 2,3,7,8-do not normally express SULT1A1, conferred 2-MeOE 2 tetrachlorodibenzo-p-dioxin (TCDD) or non-ortho-substituted sulfonation activity. The SULT1A1 allelic variants were also polychlorinated biphenyls had marked effects on E 2 metabolexpressed in Sf9 insect cells, from which post-microsomal ism through aromatic hydrocarbon receptor (AhR)-mediated supernatants were used to determine K m values of induction of cytochrome P450 1A1 (CYP1A1), an E 2 2-, 6α-and 15α-hydroxylase (12) , and cytochrome P450 1B1 (CYP1B1), an E 2 4-hydroxylase with a lesser activity at C-2
Abbreviations: CYP, cytochrome P450; E 1 , estrone; E 2 , 17β-estradiol; ER, estrogen receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GC, (13, 14) . The enzymology and regulation of phase I metabolism, ously produced estrogen metabolites.
The electrospray ion-trap system was programmed to perform three stages of MS (MS 3 ) or to monitor specific MS/MS transitions by using a selected- standard (3 pmol) and a variable amount of 2-MeOE 2 -3S (0-30 pmol). The 2-MeOE 2 -3S standard was prepared by a facile synthesis with 2-Samples of control and G/S-treated cell culture media were subjected to solidphase extraction and preparation of the trimethysilyl derivatives of the methoxyestrone (2-MeOE 1 ; Steraloids, Newport, RI) as the starting material. Sulfonation of 2-MeOE 1 at the C-3 hydroxyl was achieved by reaction with metabolites (11) . The metabolite derivatives were analyzed by GC-MS with selected-ion monitoring and quantification by stable-isotope dilution as the pyridine sulfur trioxide complex (20), which was obtained from Aldrich (Milwaukee, WI); reduction of the C-17 keto group with sodium borohydride described (11, 16) . of the vector in 100 µl of serum-free medium were combined, incubated at Total RNA was isolated as described (22) from each cell line and 5 µg room temperature for 30 min, diluted to 1 ml with 800 µl serum-free medium samples were reverse transcribed in a total volume of 20 µl using 200 and applied to each well of cells that had been previously rinsed with serumunits of Superscript II (Life Technologies, Grand Island, NY) followed by free medium. After 6 h, the medium was replaced with DC 5 medium (27) treatment with RNase H as recommended by the manufacturer. A 0.2 µl without phenol red. Seventy-two hours after transfection, cells were subcultured aliquot of the reverse-transcription reaction product was amplified by PCR at 1:16 in DC 5 medium containing 800 µg/ml Geneticin (Life Technologies). in a total reaction volume of 44 µl containing core reagents from Perkin
Materials and methods
The cells were allowed to grow for~3 weeks, after which colonies containing Elmer (Foster City, CA), TaqStart antibody (Clontech, Palo Alto, CA), Taq 500-1000 cells were isolated using cloning cylinders. These clones were extender (Stratagene, La Jolla, CA) and 1.8 mM MgCl 2 . The primers for maintained thereafter in medium containing 600 µg/ml Geneticin. After amplification of the cDNAs of five cytosolic sulfotransferases (SULTs) and sufficient growth, cells were seeded into 6-well plates, grown to confluence glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are listed in Table I and exposed to medium containing 2-MeOE 2 for assay of 2-MeOE 2 -3S together with the appropriate annealing temperatures and PCR cycle formation as described above. numbers. Primers were designed using the GCG Wisconsin Sequence
Expression of SULT1A1 in Sf9 cells Analysis Package (Madison, WI) and were designed such that each
The SULT1A1 cDNA recovered from the PCR Blunt plasmid was subcloned amplified product spanned an exon-exon junction. Each cycle consisted of into the EcoRI/BglII sites of the baculovirus transfer vector, pVL1393, and denaturation at 95°C for 10 s, annealing for 15 s and amplification at co-transfected with 0.5 µg BaculoGold DNA (Pharmingen, San Diego, CA) 72°C for 30-45 s followed by a final elongation at 72°C for 5 min. For into Sf9 cells according to the manufacturer's protocol. For expression, Sf9 analysis of the cDNAs of SULT1A1, SULT1A2 and SULT1A3 (for cells were plated at a density of 2 ϫ 10 5 cells/cm 2 in TNM-FH medium nomenclature of the SULT superfamily, see references 23 and 24), 12 µl containing 10% fetal bovine serum and amplified recombinant baculovirus of the PCR product mixture was digested with the restriction enzymes was applied at a multiplicity of infection of 10 p.f.u./cell. After 24 h, medium listed in Table II , resolved on a 2% agarose gel and stained with 0.75 was replaced and cells were cultured for an additional 48 h before harvesting. µg/ml ethidium bromide for visualization by UV-activated fluorescence.
Subcellular fractionation and assay of SULT1A1 activity Cloning of SULT1A1 from MCF-7 cells
Post-microsomal supernatant was prepared from Sf9 cells expressing SULT1A1 The entire coding sequence of SULT1A1 was amplified from cDNA or from confluent cultures of untreated MCF-7 cells. Sf9 cells were washed prepared from MCF-7 cells using the high-fidelity Vent DNA polymerase twice with phosphate-buffered saline, harvested and lysed in 50 mM potassium (New England Biolabs, Beverly, MA). Because of the high degree of phosphate buffer, pH 7.0, with 10% glycerol and 100 µg/ml phenylmethylsulhomology among the coding sequences of SULT1A1, SULT1A2 and fonyl fluoride (Sigma) with three 6 s bursts with a Polytron homogenizer SULT1A3, a reverse primer with an added BglII site (Table I) specific for (Brinkmann, Westbury, NY), followed by three 35 s bursts with a series 4710 SULT1A1 was designed in order to avoid amplifying artifactual chimeric sonicator (Cole Palmer, Vernon Hills, IL). The lysate was centrifuged at cDNAs (25). A portion of the highly conserved start sequence, CAGGAA-10 000 ϫ g for 20 min. The supernatant was recovered and centrifuged at CATG, was provided by the PCR Blunt vector (CAGG); the other portion, 100 000 ϫ g for 1 h and the post-microsomal supernatant was recovered and containing the Kozak sequence (26), was provided by the foward primer stored at -80°C prior to determination of SULT activity. The same protocol (AACATGG). After denaturation for 1 min at 95°C, 1 µl of cDNA in a was followed for preparation of the post-microsomal supernatant from MCFreaction volume of 100 µl was amplified for 27 cycles, each consisting 7 cells, except that the cells were lysed by sonication only. Incubation mixtures of denaturation at 97°C for 15 s, annealing at 70°C for 15 s and elongation for determination of SULT1A1 activity contained 5 or 45 µg of postat 72°C for 3 min, followed by a final elongation for 10 min at 72°C. microsomal supernatant from Sf9 or MCF-7 cells, respectively, 0.05-5 µM 2-After electrophoresis through 2% agarose, the band corresponding to 962 MeOE 2 , 10 µM 3Ј-phosphoadenosine 5Ј-phosphosulfate (PAPS; Sigma) and bp was excised, extracted and cloned into the PCR Blunt plasmid 10 mM potassium phosphate, pH 7.0, in a final volume of 300 µl. After (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. incubation for 10 min (Sf9) or 15 min (MCF-7 cell supernatant) at 37°C, Plasmid DNA isolated from the clones was screened by restriction [ 2 H 3 ]-2-MeOE 2 -3S was added as an internal standard and samples were endonuclease digestion with EcoRI and BglII; positive clones were verified rapidly extracted for analysis of 2-MeOE 2 -3S by electrospray ion-trap MS with selected-reaction monitoring as described above. by sequencing the entire SULT1A1 coding region. that was hydrolyzed by treatment with G/S, whereas only 27% of the 4-MeOE 2 was conjugated, and 6α-OHE 2 and 15α-OHE 2 were not conjugated. Conjugation of 2-MeOE 2 was also evident in MCF-7 cultures that had not been exposed to TCDD. In these control cultures, the medium contained 0.21 nM 2-MeOE 2 without treatment with G/S and 2.6 nM 2-MeOE 2 after treatment with G/S, indicating that 92% of the 2-MeOE 2 was in conjugated form. In the control cultures, the medium contained 1.6 nM 4-MeOE 2 without treatment with G/S and 2.0 nM 2-MeOE 2 after treatment with G/S, indicating that 19% of the 4-MeOE 2 was in conjugated form. The effect of treatment with G/S on the analytical recovery of 2-MeOE 2 in a series of nine human-derived breast-cell lines pretreated with TCDD (17) is shown in Figure 1B . Extensive conjugation of 2-MeOE 2 was evident in BT-20 cells and the ERα-positive cell lines, T-47D, ZR-75-1 and MCF-7.
Inhibition of G/S activities by SAL and Na 2 SO 4
The conjugate of 2-MeOE 2 formed in MCF-7 cells was hydrolyzed by treatment with a crude G/S preparation; however, it was not known which component, the β-glucuronidase or the aryl sulfatase, catalyzed the hydrolysis. To investigate whether MCF-7 cells metabolize 2-MeOE 2 to a sulfate or glucuronide metabolite, confluent cultures of MCF-7 cells were exposed to 3 nM 2-MeOE 2 for 4 h. Media containing the 2-MeOE 2 conjugate were treated for 6 h with G/S in the presence or absence of SAL, a glucuronidase inhibitor (28) or Na 2 SO 4 , a sulfatase inhibitor (29), before determination of unconjugated 2-MeOE 2 . Figure 2A shows that, at the end of the 4 h period, the majority of the 2-MeOE 2 was present in MCF-7 cultures as a conjugated form that was hydrolyzed by treatment with G/S; unconjugated 2-MeOE 2 in the medium was 0.55 nM. When the media were incubated with G/S in the presence of SAL, no effect on conjugate hydrolysis by investigated analytical methods for the analysis of the putative sulfate conjugate of 2-MeOE 2 . The sulfate conjugates of E 2 and estrone (E 1 ) have been analyzed with high sensitivity by Results electrospray ionization tandem MS in the negative-ion mode Conjugation of E 2 metabolites in a series of human breast- (30) . We investigated the use of similar techniques for the derived cell lines analysis of putative sulfate conjugates of 2-MeOE 2 . Experiments with synthetic 2-MeOE 2 -3S were undertaken to deterWe previously reported the effects of pretreatment with TCDD on the metabolism of E 2 in a series of human breast-derived mine the fragmentation of 2-MeOE 2 -3S and to develop methods for the analysis of this metabolite. A scan function of MS 3 cell lines (17) . Figure 1 shows these previous data but illustrates the effects of treatment with G/S on metabolite recovery by was devised for the analysis of 2-MeOE 2 -3S, which started with the isolation of the molecular anion, [M-H] -, at m/z 381. inclusion of the metabolite determinations without treating the media with G/S. Exposure of MCF-7 cultures to TCDD, which This was followed by excitation and collisional activation, causing the loss of SO 3 (80 Da) from the [M-H] -ion, producing induces expression of CYP1A1 and CYP1B1, greatly enhanced the rate of metabolism of E 2 to 2-MeOE 2 , 4-MeOE 2 , 6α-OHE 2 an ion with m/z 301. This loss of SO 3 from the [M-H] -ion occurs with estrogen 3-sulfates but not with estrogen and 15α-OHE 2 . On comparing the levels of these metabolites recovered from the media of TCDD-treated MCF-7 cells with 17β-sulfates (30), probably because the negative charge is stabilized as a phenolate ion on fragmentation of the estrogen and without treatment with G/S (Figure 1A) , it was apparent that 96% of the 2-MeOE 2 produced was in a conjugated form 3-sulfates. The m/z 301 ion was then isolated and collisionally The n-butanol fraction from extraction of culture medium from TCDDaryl sulfatase only or in the presence of 1 mM SAL or 50 mM Na 2 SO 4 for treated MCF-7 cells, which initially contained 1 µM E 2 , was analyzed by 6 h at 37°C. Unconjugated 2-MeOE 2 was analyzed as described in Materials using the same MS 3 scan function. and methods. Data are the mean Ϯ SE of four determinations. determine which members of the SULT gene family were activated and the final mass spectrum was recorded by scanning expressed in the breast-cell lines under investigation, we from m/z 80 to 400.
analyzed the mRNA expression patterns of several of the more The final mass spectrum shows, in addition to the [M-Himportant members of the SULT family by using RT-PCR. SO 3 ] -ion at m/z 301, an ion of m/z 286 ( Figure 3A ). This ion Analysis of expression of five SULT genes and the GAPDH of m/z 286 presumably arises from homolytic cleavage of the gene in nine breast-cell lines and in human liver is shown in C-O bond of the methoxy group, resulting in a loss of a Figure 4 . In order to detect differences among the expression methyl radical (15 Da) from the [M-H-SO 3 ] -ion. An advantage levels of the mRNAs, 25 cycles of PCR were used for all of the MS n experiments afforded by the ion-trap mass spectroamplifications of SULT cDNAs, whereas 21 cycles were used meter is that due to the high specificity of the fragmentafor amplification of the GAPDH cDNA, as the mRNA encoding tion pathways of individual compounds, these experiments can GAPDH is very abundant. Predicted product sizes after amplibe performed with impure samples. In Figure 3B , analysis of fication of SULT and GAPDH cDNAs are presented in Table the n-butanol fraction from extraction of MCF-7 cell culture I. Representative PCR product from amplification with each medium by using the same MS 3 sequence, m/z of the primer sets was sequenced to verify the identity of the 381→301→scan, is shown. The MCF-7 culture was exposed amplified DNA. to 10 nM TCDD for 72 h followed by 1 µM E 2 for 6 h; the Primers specific for the amplification of SULT2A1 cDNA final mass spectrum for analysis of this extract of culture (Table I) were used in the analysis shown in Figure 4A . medium ( Figure 3B ) is indistinguishable from that of the 2-No detectable amplification of the SULT2A1 sequence was MeOE 2 -3S standard ( Figure 3A) . 4F). Primers specific for the amplification of SULT1E1 cDNA tion with the primers indicated in Table I should produce 767 bp cDNA products of SULT1A1, SULT1A2 and SULT1A3. were used in the analysis shown in Figure 4B Due to the very high homology among the SULT1A1, mRNA correlated well with the observed conjugation of 2-MeOE 2 in these cell lines, as neither MDA-MB-231 nor MDA-SULT1A2 and SULT1A3 nucleotide sequences, it was not feasible to design PCR primers to amplify the SULT1A1, MB-436 cells showed conjugation of 2-MeOE 2 ( Figure 1B) . The same expression pattern of SULT1A1 mRNA was observed SULT1A2 and SULT1A3 cDNAs individually. As an alternative approach, we designed a set of primers that would amplify in cultures pretreated with 10 nM TCDD for 72 h as in the DMSO-treated control cultures (results not shown). the three cDNAs simultaneously. We then used restriction endonuclease digestion of the PCR products with StyI and In a similar way, treatment with StyI is expected to cleave the SULT1A3 PCR product into fragments of 656 and 111 bp. HindIII to distinguish among the three SULT cDNAs. Predicted sizes of the fragments produced by digestion of the SULT1A1,
The 656 bp band representing the cleavage fragment of the SULT1A3 cDNA was observed from cDNA of each SULT1A2 and SULT1A3 cDNAs with StyI and HindIII are indicated in Table II . The analysis of SULT1A1 and SULT1A3 of the cell lines and, at a very low level, with cDNA from human liver ( Figure 4C ). These results indicate that expression expression in the cell lines is shown in Figure 4C . Amplifica-of SULT1A3 mRNA did not correlate with the observed may catalyze sulfonation of 2-MeOE 2 . To investigate this hypothesis, we initiated efforts to clone a SULT1A1 cDNA pattern of 2-MeOE 2 conjugation in the cell lines, as SULT1A3 expression was observed in MDA-MB-231 and MDA-MBand express the enzyme for activity determinations. SULT1A1 DNA was obtained by performing PCR with cDNA prepared 436 cells, while neither cell line conjugated endogenously produced 2-MeOE 2 . The undigested 767 bp band observed in from MCF-7 cells using a primer set ( Table I ) that spanned the entire coding sequence of SULT1A1 and utilizing a several lanes of Figure 4C may represent heteroduplexes (31) . The analysis of SULT1A2 mRNA expression is shown in SULT1A1-specific reverse primer. This DNA was cloned into the PCR Blunt plasmid. Sequence analysis of resultant clones Figure 4D . Treatment with HindIII should cleave the SULT1A2 PCR product into fragments of 468 and 299 bp. These confirmed the presence of only SULT1A1 cDNA and revealed the presence of two SULT1A1 sequences that differed at fragments were not observed on analysis of cDNA of human liver or of any of the cell lines, indicating that the SULT1A2 nucleotide positions (numbered from ATG) 153, 162, 600 and 638. The sequences of one series of clones showed the allelic mRNA was not expressed at an appreciable level.
variants 153T, 162A, 600G and 638G (identical to GenBank Amplification of 5Ј-noncoding variants of SULT1A1 cDNA accession number X78283), and the other series of clones Results of previous molecular studies indicate that there are showed the allelic variants 153C, 162G, 600C and 638A several forms of SULT1A1 mRNA that differ in the 5Ј
(identical to GenBank accession number L19955). Only the untranslated region, resulting from alternative promoter and nucleotide substitution of A for G at position 638 results in splice sites of the RNA. To determine which of these variants an amino acid substitution, which is histidine for arginine at were expressed in the cell lines under investigation, specific codon 213. The more common 213 Arg variant is referred to primers were designed to amplify the 5Ј-untranslated regions as SULT1A1*1, whereas the 213 His variant is referred to as of SULT1A1 cDNA, exons IB, IA (32), and the intron region SULT1A1*2. We were thus able to clone cDNAs encoding between exons IA and II, referred to as exon IIA (33) or intron two polymorphic forms of SULT1A1 from MCF-7 cells. IA (34). The sequences of these primers are presented in Table  Stable transfection of SULT1A1 cDNAs in MDA-MB-231 cells I. Representative PCR products were sequenced to verify the identity of the amplified DNA. Twenty-five cycles of PCR To determine whether the SULT1A1 forms catalyze the conversion of 2-MeOE 2 to 2-MeOE 2 -3S, we performed heterologous were used for amplification such that only the more abundant cDNAs would be detected. It was necessary to digest with the cDNA-directed expression of SULT1A1*1 and SULT1A1*2.
Cultures of MDA-MB-231 cells showed no detectable restriction enzymes listed in Table II to identify the SULT1A1 PCR product, since it is possible to amplify SULT1A2 and conjugation of 2-MeOE 2 ( Figures 1B and 2B ), so this cell line was appropriate for these transfection experiments. SULT1A3 cDNAs from homologous 5Ј-untranslated regions that occur in these cDNAs (32).
SULT1A1 DNA was cloned into the expression vector, pcDNA 3.1(ϩ) and used to stably transfect MDA-MB-231 Results from the analysis of expression of the SULT1A1 exon IB transcript are shown in Figure 4E . The PCR product cells. Confluent cultures of several clones were exposed to 2-MeOE 2 for 1 h and the media were then extracted for obtained using the primers designed to amplify the cDNA of SULT1A1 exon IB (Table I ) was expected to be 959 bp and analysis of 2-MeOE 2 -3S by electrospray ion-trap MS. The mass spectrum obtained for the sequence m/z 381→301→scan yield fragments of 467 and 492 bp after digestion with StyI (Table II) . The unresolved doublet of 467 and 492 bp fragments from the analysis of the medium from a SULT1A1*2-expressing, MDA-MB-231-derived clone after exposure to was observed on analysis of cDNA of human liver and cDNAs of each of the cell lines except for MDA-MB-231 and MDA-2-MeOE 2 was indistinguishable from the analogous spectrum recorded for the 2-MeOE 2 -3S standard ( Figure 3A) , as only MB-436. The expression of SULT1A1 exon IB mRNA thus followed a very similar pattern to that seen when the primers peaks of m/z 301 and 286 were observed, and the intensity of the m/z 301 peak was 85% that of the m/z 286 peak (results that amplify the coding sequence of SULT1A1 cDNA were used ( Figure 4C) . Very little or no PCR product was observed not shown). The selected-reaction monitoring technique was used to quantify 2-MeOE 2 -3S formation in cultures of MDAwhen the primers specific for exon IA and exon IIA cDNA transcripts were used (data not shown). Only with high PCR-MB-231-derived clones stably expressing the allelic variants of SULT1A1. Several clones were obtained for both cycle numbers did we observe cDNA derived from these 5Ј-non-coding variant mRNAs. With 37 cycles of PCR, we SULT1A1*1 and SULT1A1*2 that were able to convert 2-MeOE 2 added to the medium to 2-MeOE 2 -3S, whereas stable observed a low level of expression for the exon IA splice variant of the 747 bp and 946 bp SULT1A1 PCR products in transfection in MDA-MB-231 cells with the vector alone produced only clones that were unable to produce detectable ZR-75-1 and T-47D cells. In human liver, the 747 bp variants of the SULT1A1 and SULT1A2 cDNAs were also observed.
2-MeOE 2 -3S. The rates of 2-MeOE 2 -3S formation of three representative clones were as indicated in Figure 5 . To evaluate the kinetics of SULT1A1*1 and SULT1A1*2 SULT1A3 was observed in all of the cell lines examined with forms with 2-MeOE 2 as substrate, soluble preparations of the the exception of BT-20; it was not found to be expressed in enzymes were necessary. These were readily obtained by human liver (results not shown).
expressing the two enzyme forms in Sf9 cells and preparing Cloning of SULT1A1 cDNA from MCF-7 cells post-microsomal supernatant fractions. Sulfotransferase activity in these preparations and similar ones from MCF-7 cells SULT1A1 mRNA, and specifically the exon IB mRNA variant, showed a pattern of expression in the breast-cell lines were assayed with 2-MeOE 2 as substrate and determination of the 2-MeOE 2 -3S product by electrospray ion-trap MS with ( Figure 4E ) that was consistent with the observed pattern of 2-MeOE 2 conjugation (Figure 1B) , suggesting that SULT1A1 selected-reaction monitoring. Rates of product formation were and MCF-7, in which CYP1A1 was highly induced, high rates of 2-MeOE 2 formation were observed and Ͼ90% of the 2-Discussion MeOE 2 produced was present in conjugated form. This is in contrast to what was observed with the ERα-negative cell The cell lines used in these studies were chosen to represent a wide spectrum of breast-cell types, ranging from normal lines, MDA-MB-157, MDA-MB-231 and MDA-MB-436. In MDA-MB-157 only about half of the 2-MeOE 2 was conjugated, epithelial cells to highly invasive tumor cells with metastatic potential. In our previous study (17) we found that these cell and in MDA-MB-231 and MDA-MB-436 cells no conjugation of 2-MeOE 2 was observed. Inhibition studies of the G/Stypes varied widely in the expression and inducibility of the E 2 hydroxylases, CYP1A1 and CYP1B1. In the lines derived catalyzed hydrolysis of 2-MeOE 2 conjugates in MCF-7 media suggested that this conjugation was mainly sulfation rather from normal breast epithelial cells and ERα-positive tumor cells, induction of CYP1A1 was favored over that of CYP1B1, than glucuronidation, and expression of 2-MeOE 2 sulfonation activity in MCF-7 cells was confirmed in assays employing and E 2 metabolism was primarily through the 2-hydroxylation pathway, resulting in predominantly 2-MeOE 2 formation. In electrospray ion-trap MS.
To investigate which of the SULT enzymes could potentially contrast, in the ERα-negative tumor lines, MDA-MB-231, MDA-MB-157 and MDA-MB-436, induction of CYP1B1 was be responsible for the observed conjugation of 2-MeOE 2 , we examined the expression of five of the major SULTs at the favored over that of CYP1A1, and rates of formation of 4-MeOE 2 exceeded those of 2-MeOE 2 .
mRNA level in the nine breast-cell lines by RT-PCR. We did not observe significant expression of SULT2A1 or SULT1E1 In the present study we observed another aspect of estrogen metabolism that varies among these cell lines, which was the mRNAs in any of the tumor-derived breast cell lines, which agrees well with other reports of SULT enzyme activities (35-proportion of the 2-MeOE 2 produced that was present in conjugated form. In the ERα-positive lines, T-47D, ZR-75-1 37). SULT2A1 mRNA was expressed in human liver, which agrees with previous reports of its enzyme activity (36,38). A respectively (45) . The major circulating 2-methoxyestrogen is 2-MeOE 1 , although 2-MeOE 1 and 2-MeOE 2 may be interconhigh level of expression of SULT1E1 mRNA was observed in the 184A1 immortalized breast epithelial cell line. We did not verted by the action of 17β-hydroxysteroid dehydrogenase (9). 2-MeOE 1 might also be expected to be a substrate for detect expression of SULT1A2 mRNA by RT-PCR in the breast-cell lines or in human liver, even when PCR was SULT1A1; this possibility is currently under investigation. Although the activities of SULT forms with 2-MeOE 2 as performed at high cycle numbers. SULT1A1 mRNA was found to be the major transcript in liver compared with SULT1A2 substrate have not been previously determined, the activities of a number of enzymes of the SULT gene family with several and SULT1A3 mRNAs, which agrees with a previous report (39) . SULT1A3 mRNA was expressed in all breast cells lines estrogens and other steroid hormones as substrates have been evaluated (47) . SULT2A1, which is also referred to as examined, which is consistent with a previous study of enzyme activities in several of the same cell lines (35) . dehydroepiandrosterone sulfotransferase, catalyzes the conjugation of E 2 and E 1 , but only with micromolar levels Only the expression of SULT1A1 mRNA showed a close correlation with the the pattern we observed for extensive of substrate. SULT1A3, which is also referred to as the monoamine sulfonating form of phenol sulfotransferase, conjugation of the 2-MeOE 2 formed ( Figure 1B) . Both the level of conjugation of 2-MeOE 2 and the expression of does not catalyze the sulfonation of estrogens (38) . Although both SULT1A1 (48), the phenol-sulfating form of phenol SULT1A1 mRNA were particularly high in BT-20, T-47D, ZR-75-1 and MCF-7 cells, and neither conjugation of 2-sulfotransferase, and SULT1E1 (49), or estrogen sulfotransferase, catalyze the conjugation of estrogens, SULT1E1 appears MeOE 2 nor SULT1A1 mRNA expression was observed in MDA-MB-231 or MDA-MB-436 cells. Additionally, we found to be the most efficient in catalyzing sulfation of E 2 and E 1 present at physiological, nanomolar concentrations. In MCFthat, of the different 5Ј-untranslated forms of SULT1A1 mRNA (32), the variant containing exon IB was expressed at higher 7 breast tumor cells, which do not express significant levels of SULT1E1, heterologous cDNA-directed expression of levels than those containing exons IA and IIA. Studies in human liver indicate that transcription initiation occurs most SULT1E1 suppresses E 2 -stimulated cell growth and gene expression, presumably by converting E 2 to E 2 -3-sulfate, which often 5Ј to exon IB (34). In comparing the 5Ј-flanking sequences upstream from exons IB and II in a chloramphenicol acetyl does not bind to or activate the ER (37, 50) . While SULT1E1 is active with E 2 and E 1 as substrates, it may not act on transferase expression vector transfected in human embryonal kidney cells, Bernier et al. (33) found that exon IB had the estrogen metabolites such as 2-MeOE 2 . Analysis by RT-PCR showed a high level of SULT1E1 mRNA in 184A1 cells. If higher promoter activity. The significance of these variant 5Ј-untranslated forms in tissue-specific expression is, at present, SULT1E1 is expressed in 184A1 cells, its activity did not result in significant conjugation of 2-MeOE 2 ( Figure 1B ) under unknown.
Upon cloning the SULT1A1 cDNA from MCF-7 cells, we these conditions where 2-MeOE 2 was present in TCDD-treated cultures at 22 nM. found that these cells expressed two previously characterized allelic variants, SULT1A1*1 and SULT1A1*2. Both variants, Recent studies indicate that 2-MeOE 2 is a unique, protective E 2 metabolite (reviewed in reference 9) that inhibits the when expressed in either MDA-MB-231 cells or Sf9 cells, were able to catalyze the sulfonation of 2-MeOE 2 at the C-3 proliferation of many human cancer cell lines, with breast cancer cells showing the greatest sensitivity to nanomolar hydroxyl. This is the first report of a cytosolic SULT catalyzing the sulfonation of 2-MeOE 2 . The values of K m ( Figure 6 ) for concentrations of this metabolite (51,52). 2-MeOE 2 also inhibits angiogenesis in vivo and in vitro and at higher SULT1A1*1 or SULT1A1*2 with 2-MeOE 2 as a substrate were similar to the respective values of K m determined when concentrations exhibits cytotoxicity (10, 53) . One biochemical mechanism of 2-MeOE 2 that has been identified is that, at p-nitrophenol was used as the substrate (40) (41) (42) . SULT1A1*2, which is expressed in platelets, has lower thermal stability and micromolar concentrations, 2-MeOE 2 inhibits tubulin polymerization by interacting at the colchicine-binding site (54) . Celllower activity for p-nitrophenol conjugation than SULT1A1*1 (43) . The allele frequencies of SULT1A1*1 and SULT1A1*2, free experiments in which tubulin polymerization is inhibited indicate a direct effect of 2-MeOE 2 rather than a putative respectively, are~83.2% and 16.8% in Japanese (42), 73.1% and 26.9% in Africans (44) and 68% and 32% in Caucasians conjugate; the formation of a sulfate conjugate with diminished activity may attenuate this activity. However, this interaction (40, 44) . There is some evidence that the SULT1A1*1 allozyme may be associated with protection against cell or tissue damage with tubulin may not fully account for the antitumor properties of 2-MeOE 2 that have been observed. It is conceivable that during aging, as it has been reported that there is an increasing incidence of SULT1A1*1 homozygosity and decreasing incidother effects of 2-MeOE 2 may be mediated by its conversion to 2-MeOE 2 -3S, as sulfonation of some drugs, carcinogens ence of SULT1A1*2 homozygosity with increasing age (44) .
The observed activities of SULT1A1*1 and SULT1A1*2 and endogenous steroids produces more active compounds (23,55). The formation of 2-MeOE 2 -3S catalyzed by SULTs with 2-MeOE 2 as substrate and the ability of breast-cell lines expressing SULT1A1 to conjugate nanomolar levels of 2-and the possible hydrolysis of 2-MeOE 2 -3S catalyzed by sulfatases are metabolic reactions that should be considered in MeOE 2 suggest that 2-MeOE 2 may be a physiological substrate of SULT1A1. SULT1A1 appears to show specificity for investigations of the physiological effects of 2-MeOE 2 .
In breast cells in which E 2 is converted to 2-MeOE 2 2-MeOE 2 as a substrate, as 4-MeOE 2 was conjugated to a far lesser extent, and conjugation of 6α-and 15α-OHE 2 was through enhanced metabolism elicited by AhR agonists, cell proliferation may be decreased in two ways: by removal of not observed. Concentrations of unconjugated circulating 2-methoxyestrogens range from 0.15 nM to 0.23 nM in the E 2 , which enhances proliferation in ERα-positive cells, and by production of 2-MeOE 2 , a non-estrogenic metabolite that menstrual cycle (45) , and reach 30 nM during pregnancy (45, 46) . The levels of circulating 2-methoxyestrogens in coninhibits cell proliferation. SULT1A1 may have a specific role in modulating the antiproliferative effects of 2-MeOE 2 in these jugated form are 6-and 1.5-fold higher than those of the unconjugated metabolites in ovulating and pregnant women, cell lines by catalyzing the sulfonation of 2-MeOE 2 . Expression
